HEMOSTATIC ABNORMALITIES IN COVID-19: UNDERLYING MECHANISMS AND CLUES TO TREATMENT  Do we Really See a “Storm” Never Seen Before? by Antović, Jovan
FACTA UNIVERSITATIS 
Series: Medicine and Biology Vol. 22, No 1, 2020, pp. 16 
UDC 616.98:578.834: 615.273.03(485) 
http://doi.org/10.22190/FUMB200620002A 
  
© 2020 by University of Niš, Serbia | Creative Commons License: CC BY-NC-ND 
Opinion Article 
HEMOSTATIC ABNORMALITIES IN COVID-19:  
UNDERLYING MECHANISMS AND CLUES TO TREATMENT 
Do we Really See a “Storm” Never Seen Before? 
Jovan P Antovic
1,2
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Abstract. Despite relatively short time since Covid-19 infection has appeared in the world, enormous amount of 
literature data (more than 20 000 articles currently (mid-June)) is available on PubMed. Those data, together with 
our own experience at Karolinska University Hospital point towards hemostatic abnormalities in significant number 
of severe patients. Majority of those patients experience persistent hypercoagulation with massively increased D-
dimer and fibrinogen. As a consequence, clinical thrombotic events, including venous thromboembolism (VTE) are 
common in Covid-19 patients and it seems that increased anticoagulant prophylaxis may be beneficial for severe 
(ICU/mechanical ventilation) patients. The lungs are most severely injured by the virus and that the potential 
underlying mechanism is a crosstalk between inflammation/complement and hemostasis. It is important to emphasize 
that the importance of hemostatic abnormalities in Covid-19 patients should not be overestimated since 
thromboembolic phenomena are, to a similar extent, present in other influenza and severely ill patients. 




Since December 2019, severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) has spread from 
Wuhan in China around the world [1]. In February 
2020, the WHO named the disease Covid-19. An in-
fection with increasing mortality rates and burden on the 
health care system and particularly intensive care units 
(ICU) has been experienced around the world. Infected 
patients present with influenza symptoms of different 
severity and some suffer from severe respiratory prob-
lems [2-3].  
Cytokines Disturbances in Covid-19 
In severe cases, cytokine disturbances (e.g. increased 
interleukin (IL-1B), interferon (IFN-γ), and monocyte 
chemoattractant protein 1 (MCP-1)) have been detected 
in patients with Covid-19. The authors of that initial 
article [4] have used the term “cytokine storm” which is 
considered an excessive immune response to external 
stimuli. Readers have to be aware that the pathogenesis 
of the cytokine storm is complex, it progresses rapidly 
and is associated with high mortality. It has also been 
shown that the levels of IL-2R and IL-6 in patients with 
Covid-19 are positively correlated with the severity of 
the disease [5]. Due to such changes described in China 
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among the first patients, in one of the very first articles 
it has been stated that “certain evidence shows that, 
during the coronavirus disease 2019 (COVID-19) epi-
demic, the severe deterioration of some patients has 
been closely related to the cytokine storm in their bod-
ies” [6]. Although this may be potentially true, we ad-
vise that this term be carefully used for patients with 
Covid-19 without additional evidence.  
Disseminated Intravascular Coagulation 
(DIC) in Covid-19: True or False? 
Already in February 2020, first reports about coagula-
tion abnormalities were available on the PubMed. In 
one of those studies it was reported (probably not com-
pletely correctly since it is not completely clear that 
ISTH DIC was fully properly calculated) that 71.4% of 
non-survivors with Covid-19 infection meet the criteria 
for disseminated intravascular coagulation (DIC) [7]. 
Based on the first papers, in one meta-analysis the con-
clusion that almost 3/4 of Covid-19 patients fulfilled 
laboratory criteria for disseminated intravascular coag-
ulation (DIC) was drawn [8]. The first pivotal retro-
spective study has demonstrated that increased levels of 
IL-6 were found in non-survivors in comparison to sur-
vivors but D-dimer was considered to be an even better 
prognostic factor [9]. Substantially increased D-dimer 
and its importance for disease prognosis have been ob-
served in other studies [10-12]. Our experience at Ka-
rolinska University Hospital is the same: massive in-
crease of D-dimer (even values > 35 mg/L in some pa-
tients, compared to normal values of <0,5 mg/L). D-
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dimer increases during the hospital stay in ICU, but not 
in non-intensive care patients. About 2-fold higher D-
dimer in non-survivors was observed in comparison to 
survivors (manuscript in preparation).  
However, DIC is commonly associated with bleed-
ing, after initial microthrombosis in different organs, 
due to the consumption of coagulation factors, fibrino-
gen and platelets. Very soon, it was observed that the 
Covid-19 coagulation abnormalities pattern is different. 
In the majority of patients prothrombin time (PT) was 
normal, while fibrinogen was even increased [13]. In 
our laboratory, we have observed fibrinogen levels ap-
proximately 1.5-2 times above the limit of the reference 
range during intra-hospital course (longer than 2 weeks 
in the majority of cases), in both survivors and non-
survivors. Although thrombocytopenia was described in 
some cohorts [14, 15] it does not seem to be a common 
finding. In our cohort initially normal platelet count was 
observed, with an increase later during the hospital stay 
both in ICU and in non-ICU patients (even more sig-
nificantly in the survivors). 
Clinical Manifestations of Coagulation 
Abnormalities 
Clinical manifestations of coagulation abnormalities are 
very different. The majority of patients have acute res-
piratory distress (ARDS) or ARDS like conditions, but 
many patients experience deep vein thrombosis (DVT) 
and particularly pulmonary embolism (PE). Some pa-
tients have arterial thrombotic events. In one study, it has 
been observed that 31% of patients experienced some 
thrombotic events, primarily venous [17]. The impression 
of ICU doctors at Karolinska University Hospital is that 
this number may be even higher (up to 40%) (personal 
communication). However, some patients develop pe-
ripheral and acro-ischemic necrosis typical of thrombotic 
microangiopathies (TMA) (including antiphospholipid 
syndrome (APS) and DIC) [18]. 
Although an association between Covid-19 and an-
tiphospholipid antibodies (syndrome) has been de-
scribed [19, 20] there is no consensus and several de-
bates have been raised about this issue [21].We at Ka-
rolinska University laboratory started to get more sam-
ples from patients suspected to have antiphospholipid 
syndrome (APS), heparin-induced thrombocytopenia 
(HIT) or thrombotic thrombocytopenic purpura (TTP) 
like syndromes. All those conditions belong to TMA 
and may indicate close association between coagulation 
and inflammation. But we cannot state that we have 
observed a significant increase of positive results which 
could indicate a clear association between Covid-19 
positivity and the presence of those TMA syndromes. 
However, some unusual findings such as pseudothrom-
bocytopenia have been described in Covid-19 [22]. This 
laboratory in-vitro phenomenon caused by platelet ag-
gregation in the tube has been observed in one patient 
with Covid-19 in our laboratory. The author of this re-
view has never seen HIT associated with platelet aggre-
gation in the tube for 15 years of his laboratory career 
(some very seldom cases were described in the litera-
ture). Therefore, he was completely sure that there was 
no HIT in that patient. But both rapid (PaGIA) and 
ELISA tests were strongly positive and the functional 
platelet aggregation assay was also positive. Most im-
portantly, after the cessation of heparin treatment and its 
replacement with Apixaban platelets increased. All 
those findings indicated clinically relevant HIT associ-
ated with (if not a consequence of) the Covid-19 infec-
tion (manuscript in preparation). 
Anticoagulant Treatment in Covid-19 
It has been shown that anticoagulant treatment decreases 
mortality from Covid-19 [22] and Karolinska University 
Hospital was among the first to introduce clear 
recommendations for anticoagulant treatment in these 
patients. Additionally, some specific recommendations as 
the double dose prophylaxis in hospitalized patients with, 
among other risk factors, D-dimer above 3 mg/L and/or 
fibrinogen over 8 g/L were given by Karolinska University 
Hospital coagulation experts very early (at the beginning of 
April 2020). This approach has not been widely accepted 
yet, and most consensus statement recommendations are 
based on more conventional standard dose prophylaxis 
[23]. Interestingly we have observed significant decrease 
of D-dimer after the introduction of an increased 
prophylactic LMWH dose (manuscript in preparation). It 
also seems that such an approach decreases mortality, but 
final evaluation is yet to be done. 
  
Table 1 ISTH DIC score [16] 
 0 1 2 
Platelet count >100  10
9
/ml 50-100  10
9
/ml <50  10
9
/ml 
D-dimer* No increase Moderate increase (2) Strong increase (3) 
Prolonged PT < 3s 3-6s >6s 
Fibrinogen > 1g/L < 1g/L  
>5 overt DIC; D-dimer 2 instead of 1 and 3 instead of 2 points for moderate and strong increase 
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Potential Mechanisms of Thrombo-
Inflammatory Conditions in Covid-19 
It seems that the lungs are most severely injured by this 
virus and that the underlying mechanism is the release 
of pro-inflammatory cytokines and extravasation of 
blood cells, primarily neutrophils. At the same time, it is 
well known that the complement system is an important 
part of the innate immunity to viral infections. The link 
between complement and hemostasis has been inten-
sively investigated in recent years [for a review see 24]. 
Additionally, both microparticles (MP), microvesicles 
(< 1 µm) released from different cells after activation 
and/or apoptosis[25] and neutrophil extracellular traps 
(NETs)[26] which represent part of the host defense are 
involved in the signaling process and communication 
between inflammation/complement and hemostasis. 
First pathohistological and autopsy reports are now 
available, and they demonstrate both the deposition of 
fibrin, neutrophils and C5b-9 and C4d in the lungs and 
peripheral tissues [27].  
MPs, vesicles rich in phosphatidylserine (PS) that 
carry a subset of parent-cell proteins, are released pri-
marily from platelet and endothelial cells but many 
other cells may also be the source of MPs and they can 
carry different proteins including complement, as it has 
been shown in patients with systemic disease such as 
vasculitis [28]. It has also been shown in another syn-
drome (APS), commonly associated with TMA, that 
thrombin activatable fibrinolysis inhibitor (TAFI), 
which is included in the stabilization of fibrin, may rep-
resent a link between coagulation and complement [29]. 
In one recent review, it has been discussed the associa-
tion between brain injury (commonly associated with 
DIC or DIC-like coagulation abnormalities which have 
common features as some of Covid-19 coagulopathy), 
hemostasis and complement [30]. 
Neutrophil extracellular traps (NETs) were first de-
scribed in 2004 as a means for neutrophils to trap and kill 
bacteria and are released as a result of a programmed cell 
death mechanism referred to as NETosis. The most recent 
study revealed high levels of NETs in many patients with 
Covid-19, where they may have contributed to cytokine 
release and respiratory failure [31]. 
Are Hemostatic Disturbances in Covid-19 
Unique – Implications for Treatment? 
Despite dramatical clinical and laboratory findings and 
massive overload of “scientific” information (at the 
moment of writing this article (mid-June 2020) more 
than 20,000 articles including the term Covid are avail-
able on PubMed) based mostly on case-reports and 
small series of patients (published without a thorough 
peer-review process) medical practitioners dealing with 
thrombosis and hemostasis have to keep the ability for 
logical decision making based on scientific evidences. 
Therefore, we should carefully think about the fact that 
increased D-dimer is common in hospitalized and criti-
Table 2 Karolinska University Hospital anticoagulant treatment recommendations 
All adult patients hospitalized with (suspected) Covid 19(Plt> 3010
9
/L, no bleeding) 
< 50 kg Fragmin® 2500E alt. Innohep® 3500 E  1sc 
50–90 kg Fragmin® 5000E alt. Innohep® 4 500 E  1 sc 
> 90 kg Fragmin® 75E/kg alt. Innohep® 75E/kg 1 sc 
All adult patients with Covid-19 hospitalized at ICU  
and/or D-D > 3 mg/L, fibrinogen> 8 g/L, cancer, previous thrombosis, thrombophilia 
< 50 kg Fragmin® 2500E alt. Innohep® 3500 E  2 sc 
50–90 kg Fragmin® 5000E alt. Innohep® 4 500 E  2 sc 
> 90 kg Fragmin® 75E/kg alt. Innohep® 75E/kg  2sc 
eGFR < 30ml / min: Consider 30% dose reduction.  
High dose prophylaxis can be monitored with antiFXa after 3–5 doses due to accumulation risk, target through level 
antiFXa below 0.3 kIE/L. 
All adult patients with Covid-19 hospitalized with VTE (or strong suspicion for VTE) 
Alt. 1. Fragmin® 200E/kg x1 alt Innohep® 175E/kg x1 
Bad clinical efficacy or extensive VTE: Fragmin® 120E / kg 2 alt. Innohep® 100E / kg 2. Higher doses lack evidence 
but increase the risk of bleeding! 
eGFR < 30ml/min: Consider 30% dose reduction.  
Full dose treatment can be monitored with antiFXa after 3–5 doses due to accumulation risk, target through level antiFXa 
below 0.6 kIE/L. 
Alt. 2. Heparin infusion with monitoring of APTT 
If it is difficult to achieve therapeutic APTT, control anti-FXa and antithrombin (AT); 
Targeted antiFXa 0.3-0.7 kIE/L for heparin infusion. 
If AT < 0.6 kIE/L, antithrombin substitution may be considered. 
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cally ill patients [32-34] but is not routinely measured 
on a daily basis in other patients as is currently being 
done in patients with COVID-19 [35]. Increased inci-
dence of VTE is not exclusively present in Covid-19. 
Even in other viral influenza (H1N1) it was observed 
that severe patients with ARDS who were positive to 
H1N1 had 20-fold higher risk to develop VTE, and anti-
coagulation dramatically decreased that risk [36]. 
Nevertheless, it seems that apart from ARDS or 
ARDS like syndromes some kind of thromboembolic 
complications (mostly VTE) are present in about one 
third of severe (mostly ICU) patients with Covid-19. 
However, one should be reminded that venous thrombo-
embolism was present in approximately the same (or 
even higher, up to 40%) percentage on routine autopsies 
and that the number was the same within several dec-
ades [37, 38]. The same number of VTE (40%) was 
found in the very first larger series of autopsies of pa-
tients who died after Covid-19 [39]. Interestingly 
enough, although now there is a definite consensus that 
coagulation abnormalities in Covid-19 are not similar to 
those in DIC, mortality in overt DIC is also described to 
be about 40% [40]. So almost a philosophical question 
should be raised: are hemostatic abnormalities some-
thing that happens at the end of life in severely ill pa-
tients irrespectively of whether they have Covid-19, 
another influenza or some other severe terminal dis-
ease? It also seems that the proinflammatory response is 
also a part of those pathophysiological conditions. 
Taking into account the preliminary results that the use 
of anticoagulation not only decreases the incidence of VTE 
but also seems to improve the outcome of severe patients 
with Covid-19, a question may be posed the other way 
round: Should (all) severely ill patients may experience the 
benefit of increased anticoagulation prophylaxis? 
Table 3 Karolinska University Hospital coagulation 
findings in patients with severe Covid-19 
Analysis Change Kinetics during hospitalization 
PT-INR N  
Fibrinogen   
Platelet count N/ 
*
 
D-dimer   
N-normal,  increase,  major increase,  preserve on initial 
level. 
*Non-survivors had slight platelet count decrease (within 
reference range between day 5 and 10). 
Instead of Conclusions 
To summarize what is known about thrombo-inflamma-
tory abnormalities in Covid-19 (both from the literature 
and from Karolinska University Hospital experience): 
1. High levels of inflammatory markers, particu-
larly IL-6, neutrophils, fibrinogen and D-dimer 
are present and are associated with prognosis; 
2. Almost 40% of severe patients apart from ARDS-
like phenomena develop thrombosis, predomi-
nantly VTE/PE but also arterial thrombosis and 
TMA type changes in peripheral organs including 
acro-necrosis; 
3. Pathophysiologically, complement-neutrophils-
fibrin deposition is present in affected tissues 
(primarily the lungs); 
4. Increase of the prophylactic dose of hepa-
rin/LMWH seems to be justified in the preven-
tion of thrombosis. 
What is not certainly known: 
1. Is thrombocytopenia or thrombocytosis more 
common in Covid-19 patients? 
2. Is the mechanism behind large vessel thrombosis 
and TMA the same? 
3. How to diagnose thrombosis? 
4. How to manage thrombosis (primarily VTE/PE) 
not responding to the standard treatment? 
5. Is there a place for antiplatelet treatment in addi-
tion to anticoagulation treatment? 
6. Does the level of complement activation corre-
late with the development of thrombosis propen-
sity and severe pulmonary engagement? 
7. Are there changes in additional modulators of 
hypercoagulability, such as microparticles and 
neutrophil extracellular traps, which contribute to 
the complex interplay of hemostasis, inflamma-
tion and the SARS-Cov2 infection? 
Hemostatic abnormalities including VTE are common 
in Covid-19 and it seems that increased anticoagulant 
prophylaxis may be beneficial for severe (ICU/mechanical 
ventilation) patients. However, the importance of those 
changes should not be overestimated since it seems that 
thromboembolic phenomena are, to a similar extent, 
present in other influenza and severely ill patients.  
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